Cargando…

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma

BACKGROUND: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Liqing, Zhang, Jian, Li, Minghao, Xu, Nan, Qi, Wei, Tan, Jingwen, Lou, Xiaoyan, Yu, Zhou, Sun, Juanjuan, Wang, Zhenkun, Fu, Chengcheng, Tang, Xiaowen, Dai, Haiping, Chen, Jia, Wu, Depei, Yu, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222432/ https://www.ncbi.nlm.nih.gov/pubmed/32435496 http://dx.doi.org/10.1186/s40364-020-00192-6

Ejemplares similares

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes
por: Kang, Liqing, et al.
Publicado: (2020)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement
por: Zhang, Ying, et al.
Publicado: (2021)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
por: Tan, Jingwen, et al.
Publicado: (2022)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
por: Du, Zhicheng, et al.
Publicado: (2023)

Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient
por: Wang, Li-xia, et al.
Publicado: (2021)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
por: Zhang, Xi, et al.
Publicado: (2022)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
por: Hu, Dingyuan, et al.
Publicado: (2023)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
por: Lee, Holly, et al.
Publicado: (2023)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2020)

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma
por: Ladd, Alden, et al.
Publicado: (2015)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
por: Bu, De-Xiu, et al.
Publicado: (2018)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
por: Abramson, Hanley N.
Publicado: (2020)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Construction of Chimeric Dual-Chain Avidin by Tandem Fusion of the Related Avidins
por: Riihimäki, Tiina A., et al.
Publicado: (2011)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i82064fv6vpuegkdqb7vcm02h2